Welcome to Galantos Pharma GmbH

Galantos Pharma is a biopharmaceutical company focusing on the research and development of novel drugs for the treatment of neurodegenerative diseases, in particular Alzheimer‘s Disease (AD).

Galantos Pharma GmbH was founded in 2005 in Mainz by professors Alfred Maelicke (Mainz) and Ulrich Jordis (Vienna) who both have been crucially involved in the development of the natural product galantamine for the treatment of AD.

Galantos is developing Memogain, a derivative  of the plant alkaloid galantamine, for symptomatic and disease-modifying treatment of Alzheimer‘s dementia (AD). The goal is to improve efficacy and abolish gastrointestinal side effects. At present, Memogain has successfully completed preclinical development and is ready for clinical testing. Phase I clinical studies are planed at CHDR, Leiden (NL), with the study design permitting proof of concept already at this early stage of development.

Due to financial limitations, Galantos has recently closed its research laboratories and tentatively stopped development of  new neuroprotective and disease-modifying drugs for AD treatment. The government (BMBF) co-funded project focussed on Galantos' experience with allosteric modulators of nicotinic receptors and was performed in collaboration with acedemic and CRO experts.

Click here for further information on Memogain

To download a Company Profile of Galantos, please click here.